MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Revenue
$4,983M
Net Income
$451M
Net Profit Margin
9.05%
EPS
$1.37
Unit: Million (M) dollars
Revenue Breakdown
US
Non Us
Revenue Breakdown
Medical Essentials
Interventional
Connected Care
Bio Pharma Systems
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenues
4,983
4,714
5,252
5,891
Cost of products sold
2,668
2,560
2,841
3,092
Selling and administrative expense
1,261
1,213
1,393
1,367
Research and development expense
258
249
306
323
Integration, restructuring and transaction expense
89
533
111
129
Other operating expense, net
-44
-66
-50
-285
Total operating costs and expenses
4,320
4,620
4,700
5,194
Operating income
663
93
552
698
Interest expense
132
149
153
155
Interest income
4
9
4
5
Other income (expense), net
19
86
-10
-36
Income from continuing operations before income taxes
554
39
393
509
Income tax provision
102
76
11
16
Net income from continuing operations
451
-37
-
493*
Loss from discontinued operations, net of tax
-
-
-
0*
Net income
-
-
382
493
Preferred stock dividends
-
-
-
0
Net income applicable to common shareholders
-
-
-
493
Basic EPS
1.37
-1.11
1.34
1.72
Diluted EPS
1.37
-1.11
1.34
1.708
Basic Average Shares
274,788,000
280,640,000
285,582,000
286,624,000
Diluted Average Shares
275,158,000
280,640,000
285,845,000
288,687,000
Page 1
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
1
2
US
$3,081M
(-3.14%↓ Y/Y)
Non Us
$1,902M
(-18.30%↓ Y/Y)
Revenues
$4,983M
(-9.55%↓ Y/Y)
Operating income
$663M
(-24.83%↓ Y/Y)
Other income
(expense), net
$19M
(157.58%↑ Y/Y)
Interest income
$4M
(-20.00%↓ Y/Y)
Total operating costs
and expenses
$4,320M
(-6.63%↓ Y/Y)
Income from continuing
operations before income...
$554M
(-21.19%↓ Y/Y)
Interest expense
$132M
(-13.16%↓ Y/Y)
Cost of products sold
$2,668M
(-7.20%↓ Y/Y)
Selling and
administrative expense
$1,261M
(-4.47%↓ Y/Y)
Research and development
expense
$258M
(-13.13%↓ Y/Y)
Integration, restructuring
and transaction...
$89M
(-8.25%↓ Y/Y)
Other operating
expense, net
-$44M
(-15.79%↓ Y/Y)
Net income from
continuing operations
$451M
Income tax provision
$102M
(-20.93%↓ Y/Y)
Buy us a coffee
header-bd-logo-svg
BECTON DICKINSON & CO (BDX)
header-bd-logo-svg
BECTON DICKINSON & CO (BDX)